iRadimed (IRMD) vs NovoCure (NVCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
iRadimed (IRMD) has outperformed NovoCure (NVCR) over the past year, gaining 11.7% versus a loss of 0.9%. Over five years, IRMD leads with a +134.2% price change compared with -87.3% for NVCR. NovoCure is the larger company by market cap ($1.66 billion vs $1.10 billion), about 1.5 times the size.
iRadimed pays a dividend yielding 0.90%, while NovoCure does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRMD | NVCR |
|---|---|---|
| Share price | $85.88 | $14.22 |
| Market cap | $1.10B | $1.66B |
| 1-day change | +0.48% | -3.00% |
| YTD return | -11.72% | +9.98% |
| 1-year return | +11.72% | -0.91% |
| 5-year return | +134.20% | -87.33% |
| P/E ratio (TTM) | 47.98 | — |
| Forward P/E | 35.01 | — |
| EPS (TTM) | $1.79 | $-1.30 |
| Dividend yield | 0.90% | 0.00% |
| Annual dividend | $0.77 | $0.00 |
| 52-week high | $107.90 | $21.45 |
| 52-week low | $71.34 | $9.82 |
| Distance from 52-week high | -20.41% | -33.71% |
| Analyst consensus | none | buy |
| Avg. price target upside | +37.40% | +88.89% |
| Average volume | 125.83K | 1.42M |
| Shares outstanding | 12.79M | 116.45M |
| Employees | 166 | 1,605 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRMD has outperformed NVCR by 12.6 percentage points over the past year.
About iRadimed
IRMD stock →IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device.
Health Care · Medical/Dental Instruments · 166 employees
About NovoCure
NVCR stock →NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Health Care · Medical/Dental Instruments · 1,605 employees
IRMD vs NVCR FAQ
Which is bigger, iRadimed or NovoCure?
NovoCure (NVCR) is larger, with a market capitalization of $1.66B compared with $1.10B for iRadimed (IRMD).
Which stock has performed better over the past year, IRMD or NVCR?
IRMD returned +11.72% over the past 12 months, compared with -0.91% for NVCR (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, iRadimed or NovoCure?
iRadimed pays a dividend yielding 0.90%, while NovoCure does not currently pay a regular dividend.
Are iRadimed and NovoCure in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.